CFG
AKBA icon

Carr Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Carr Financial Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8K Hold
15,581
– – ﹤0.01% 182
2026
Q1 		$21.7K Buy
15,581
+4,000
+35% +$5.5K 0.01% 174
2025
Q4 		$18.6K Buy
+11,581
New +$24.2K 0.01% 186

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Carr Financial Group's AKBA Position: Q2 2026 in Review

Carr Financial Group held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 15,581 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #182.

Carr Financial Group first reported a position in AKBA in Q4 2025 and has held it in 3 quarters since. The position peaked at $21.7K in Q1 2026. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Carr Financial Group held 15,581 shares of Akebia Therapeutics worth $17.8K as of Q2 2026.
  • Carr Financial Group left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Carr Financial Group's portfolio in Q2 2026, its #182 holding.
  • Carr Financial Group first reported a position in Akebia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Carr Financial Group's Akebia Therapeutics position peaked at $21.7K in Q1 2026.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Carr Financial Group's 13F filing for Q2 2026, filed 6 Aug 2026.